2020 IPO

Moderna Therapeutics Stock

Moderna Therapeutics specializes in drug discovery and drug development based on messenger RNA.

Sign up today and learn more about Moderna Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

Founded

2010

Notable Investors

Sequoia Capital

Headquarters

Cambridge MA, US

Total Funding

$1.8B

About Moderna Therapeutics Stock

Moderna Therapeutics develops messenger RNA therapeutics. Itprovides in vivo drug modality that produces human proteins or antibodies inside patient cells. Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilic and blood factors, and oncology.

Investors

Funding History

December 2012$40.0M
October 2013$24.6M
November 2013$110M
January 2014$25.0M
January 2015$450M
January 2016$20.0M
August 2016$474M
September 2016$8.0M
February 2018$500M
May 2018$125M

Management

Chief Executive Officer

Stéphane Bancel

President

Stephen Hoge

Chief Financial Officer

Lorence Kim

Chief Digital Officer

Marcello Damiani

Chief Human Resources Officer

Annie Drapeau

Chief Sustainability Officer and Chief of Staff

Stephen Harbin

Chief Corporate Affairs Officer

Megan Pace

Chief Medical Officer

Tal Zaks

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo